The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Hepatitis B cure: From discovery to regulatory approval
Open accessAbstract
The majority of persons currently treated for chronic hepatitis B require long‐term or lifelong therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and immune modulatory therapies are in development. The introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisal of the efficacy and safety of these treatments and definitions of new or additional endpoints to inform clinical trials. To move the field forward and to expedite the pathway from discovery to regulatory approval, a workshop with key stakeholders was held in September 2016 to develop a consensus on treatment endpoints to guide the design of clinical trials aimed at hepatitis B cure. The consensus reached was that a complete sterilizing cure, i.e., viral eradication from the host, is unlikely to be feasible. Instead, a functional cure characterized by sustained loss of hepatitis B surface antigen with or without hepatitis B surface antibody seroconversion, which is associated with improved clinical outcomes, in a higher proportion of patients than is currently achieved with existing treatments is a feasible goal. Development of standardized assays for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with development of novel antiviral and immune modulatory therapies such that approval of new treatments can be linked to the approval of new diagnostic assays used to measure efficacy or to predict response. Combination of antiviral and immune modulatory therapies will likely be needed to achieve functional hepatitis B virus cure. Limited proof‐of‐concept monotherapy studies to evaluate safety and antiviral activity should be conducted prior to proceeding to combination therapies. The safety of any new curative therapies will be paramount given the excellent safety of currently approved nucleos(t)ide analogues. (H epatology 2017).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Chang, T.-T., Liaw, Y.-F., Wu, S.-S., Schiff, E., Han, K.-H., Lai, C.-L., Safadi, R., Lee, S. S., Halota, W., Goodman, Z., et al. (2010) · Hepatology · doi:10.1002/hep.23785 · Cited by 972
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., et al. (2014) · Science · doi:10.1126/science.1243462 · Cited by 893
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
Maini, M. K., Boni, C., Lee, C. K., Larrubia, J. R., Reignat, S., Ogg, G. S., King, A. S., Herberg, J., Gilson, R., Alisa, A., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.8.1269 · Cited by 800
Yang, H.-I., Yuen, M.-F., Chan, H. L.-Y., Han, K.-H., Chen, P.-J., Kim, D.-Y., Ahn, S.-H., Chen, C.-J., Wong, V. W.-S., & Seto, W.-K. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70077-8 · Cited by 669
Yuen, M.-F., Tanaka, Y., Fong, D. Y.-T., Fung, J., Wong, D. K.-H., Yuen, J. C.-H., But, D. Y.-K., Chan, A. O.-O., Wong, B. C.-Y., Mizokami, M., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.023 · Cited by 584
Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., Petersen, J., Raimondo, G., Dandri, M., & Levrero, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58847 · Cited by 577
Tseng, T., Liu, C., Yang, H., Su, T., Wang, C., Chen, C., Kuo, S. F., Liu, C., Chen, P., Chen, D., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.007 · Cited by 574
Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., Calleja, J. L., Chi, H., Manolakopoulos, S., Mangia, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.035 · Cited by 557
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
Decorsière, A., Mueller, H., van Breugel, P. C., Abdul, F., Gerossier, L., Beran, R. K., Livingston, C. M., Niu, C., Fletcher, S. P., Hantz, O., et al. (2016) · Nature · doi:10.1038/nature17170 · Cited by 551
Fisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., Cavallo, M. C., Silini, E. M., Andreone, P., Missale, G., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.052 · Cited by 488
Bertoletti, A., & Ferrari, C. (2012) · Gut · doi:10.1136/gutjnl-2011-301073 · Cited by 477
Mason, W. S., Gill, U. S., Litwin, S., Zhou, Y., Peri, S., Pop, O., Hong, M. L. W., Naik, S., Quaglia, A., Bertoletti, A., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.012 · Cited by 449
Masuzaki, R., Tateishi, R., Yoshida, H., Goto, E., Sato, T., Ohki, T., Imamura, J., Goto, T., Kanai, F., Kato, N., et al. (2009) · Hepatology · doi:10.1002/hep.22870 · Cited by 435
Sato, S., Li, K., Kameyama, T., Hayashi, T., Ishida, Y., Murakami, S., Watanabe, T., Iijima, S., Sakurai, Y., Watashi, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.016 · Cited by 413
Yuen, M., Wong, D. K., Fung, J., Ip, P., But, D., Hung, I., Lau, K., Yuen, J. C., & Lai, C. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.008 · Cited by 409
Buster, E. H. C. J., Flink, H. J., Cakaloglu, Y., Simon, K., Trojan, J., Tabak, F., So, T. M. K., Feinman, S. V., Mach, T., Akarca, U. S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.031 · Cited by 393
Jung, K. S., Kim, S. U., Ahn, S. H., Park, Y. N., Kim, D. Y., Park, J. Y., Chon, C. Y., Choi, E. H., & Han, K.-H. (2011) · Hepatology · doi:10.1002/hep.24121 · Cited by 388
Lanford, R. E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V. L., Brasky, K. M., Fosdick, A., Frey, C. R., Zheng, J., Wolfgang, G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.003 · Cited by 377
Boni, C., Laccabue, D., Lampertico, P., Giuberti, T., Viganò, M., Schivazappa, S., Alfieri, A., Pesci, M., Gaeta, G. B., Brancaccio, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.014 · Cited by 377
Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes
Urban, S., Bartenschlager, R., Kubitz, R., & Zoulim, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.030 · Cited by 361
Self-citationMarcellin, P., Ahn, S. H., Ma, X., Caruntu, F. A., Tak, W. Y., Elkashab, M., Chuang, W.-L., Lim, S.-G., Tabak, F., Mehta, R., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.09.043 · Cited by 342
Lee, M.-H., Yang, H.-I., Liu, J., Batrla-Utermann, R., Jen, C.-L., Iloeje, U. H., Lu, S.-N., You, S.-L., Wang, L.-Y., & Chen, C.-J. (2013) · Hepatology · doi:10.1002/hep.26385 · Cited by 322
Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B
Kennedy, P. T. F., Sandalova, E., Jo, J., Gill, U., Ushiro–Lumb, I., Tan, A. T., Naik, S., Foster, G. R., & Bertoletti, A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.009 · Cited by 307
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.
Rehermann, B., Lau, D., Hoofnagle, J. H., & Chisari, F. V. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118592 · Cited by 294
Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection
Yang, H.-I., Sherman, M., Su, J., Chen, P.-J., Liaw, Y.-F., Iloeje, U. H., & Chen, C.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4456 · Cited by 281
Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., Möller, I., Seiz, P., Glebe, D., Wang, B., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003856 · Cited by 251
Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B
Park, J.-J., Wong, D. K., Wahed, A. S., Lee, W. M., Feld, J. J., Terrault, N., Khalili, M., Sterling, R. K., Kowdley, K. V., Bzowej, N., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.050 · Cited by 249
Self-citationTropberger, P., Mercier, A., Robinson, M., Zhong, W., Ganem, D. E., & Holdorf, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518090112 · Cited by 246
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Lok, A. S. F., Wu, P.-C., Lai, C.-L., Lau, J. Y. N., Leung, E. K. Y., Wong, L. S. K., Ma, O. C. K., Lauder, I. J., Ng, C. P. L., & Chung, H.-T. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90337-x · Cited by 242
Self-citationFattovich, G., Giustina, G., Realdi, G., Corrocher, R., & Schalm, S. W. (1997) · Hepatology · doi:10.1002/hep.510260536 · Cited by 229
Blank, A., Markert, C., Hohmann, N., Carls, A., Mikus, G., Lehr, T., Alexandrov, A., Haag, M., Schwab, M., Urban, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.013 · Cited by 221
Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy
Lai, C.-L., & Yuen, M.-F. (2013) · Hepatology · doi:10.1002/hep.25937 · Cited by 208
Menne, S., Tumas, D. B., Liu, K. H., Thampi, L., AlDeghaither, D., Baldwin, B. H., Bellezza, C. A., Cote, P. J., Zheng, J., Halcomb, R., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.026 · Cited by 208
Janssen, H. L. A., Brunetto, M. R., Kim, Y. J., Ferrari, C., Massetto, B., Nguyen, A.-H., Joshi, A., Woo, J., Lau, A. H., Gaggar, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.027 · Cited by 203
Trained immunity in newborn infants of HBV-infected mothers
Hong, M., Sandalova, E., Low, D., Gehring, A. J., Fieni, S., Amadei, B., Urbani, S., Chong, Y.-S., Guccione, E., & Bertoletti, A. (2015) · Nature Communications · doi:10.1038/ncomms7588 · Cited by 192
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
Gane, E. J., Lim, Y.-S., Gordon, S. C., Visvanathan, K., Sicard, E., Fedorak, R. N., Roberts, S., Massetto, B., Ye, Z., Pflanz, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.037 · Cited by 190
The immune tolerant phase of chronic HBV infection: new perspectives on an old concept
Bertoletti, A., & Kennedy, P. T. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.79 · Cited by 189
Suzuki, F., Miyakoshi, H., Kobayashi, M., & Kumada, H. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21339 · Cited by 182
Lok, A. S., Pan, C. Q., Han, S.-H. B., Trinh, H. N., Fessel, W. J., Rodell, T., Massetto, B., Lin, L., Gaggar, A., Subramanian, G. M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.016 · Cited by 178
Self-citationChan, H. L. Y., Chan, C. K., Hui, A. J., Chan, S., Poordad, F., Chang, T.-T., Mathurin, P., Flaherty, J. F., Lin, L., Corsa, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.044 · Cited by 172
Liu, F., Campagna, M., Qi, Y., Zhao, X., Guo, F., Xu, C., Li, S., Li, W., Block, T. M., Chang, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003613 · Cited by 161
Klumpp, K., Lam, A. M. I., Lukacs, C., Vogel, R., Ren, S., Espiritu, C., Baydo, R. O., Atkins, K., Abendroth, J. A., Liao, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513803112 · Cited by 155
PD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model
Tzeng, H.-T., Tsai, H.-F., Liao, H., Lin, Y.-J., Chen, L., Chen, P., & Hsu, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039179 · Cited by 152
Immune Response in Hepatitis B Virus InfectionPreprint
Tan, A. T., Koh, S., & Bertoletti, A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021428 · Cited by 146
Kim, G., Lee, H. C., Kim, M.-J., Ha, Y., Park, E. J., An, J., Lee, D., Shim, J. H., Kim, K. M., & Lim, Y. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.031 · Cited by 145
Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA
Seeger, C., & Sohn, J. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.94 · Cited by 140
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
Gish, R. G., Yuen, M., Chan, H. L., Given, B. D., Lai, C., LOCARNINI, S. A., Lau, J. Y. N., Wooddell, C. I., Schluep, T., & Lewis, D. L. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.019 · Cited by 135
Liu, J. B., Yang, H., Lee, M., Jen, C., Batrla‐Utermann, R., Lu, S., Wang, L., You, S., & Chen, C. (2016) · Hepatology · doi:10.1002/hep.28552 · Cited by 135
STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus
Guo, F., Han, Y., Zhao, X., Wang, J., Liu, F., Xu, C., Wei, L., Jiang, J., Block, T. M., Guo, J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04321-14 · Cited by 130
Management of Hepatitis B: Our Practice and How It Relates to the Guidelines
Yapalı, S., Talaat, N., & Lok, A. S.-F. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.036 · Cited by 116
Self-citationde Lédinghen, V., Vergniol, J., Barthe, C., Foucher, J., Chermak, F., Bail, B. L., Merrouche, W., & Bernard, P. ‐. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12307 · Cited by 112
Seto, W., Wong, D. K.-H., Fung, J., Huang, F., Lai, C., & Yuen, M. (2013) · Hepatology · doi:10.1002/hep.26376 · Cited by 107
Gaggar, A., Coeshott, C. M., Apelian, D., Rodell, T. C., Armstrong, B. R., Shen, G., Subramanian, G. M., & McHutchison, J. G. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.027 · Cited by 99
Kim, S. U., Lee, J. H., Kim, D. Y., Ahn, S. H., Jung, K. S., Choi, E. H., Park, Y. N., Han, K., Chon, C. Y., & Park, J. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036676 · Cited by 98
Venkatakrishnan, B., Katen, S. P., Francis, S., Chirapu, S. R., Finn, M. G., & Zlotnick, A. (2016) · Journal of Virology · doi:10.1128/jvi.03058-15 · Cited by 88
Manesis, E. K., Papatheodoridis, G., TINIAKOS, D. G., Hadziyannis, E. S., Agelopoulou, O. P., Syminelaki, T., Papaioannou, C., Nastos, T., & Karayiannis, P. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.027 · Cited by 71
Korolowicz, K. E., Iyer, R. P., Czerwinski, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161313 · Cited by 71
Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus
Ely, A., Moyo, B., & Arbuthnot, P. B. (2016) · Molecular Therapy · doi:10.1038/mt.2016.43 · Cited by 41
Li, W., Zhao, J., Zou, Z., Liu, Y., Li, B., Sun, Y. H., Li, X., Liu, S., Cai, S.-P., Yao, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089046 · Cited by 35
Cheng, H., Kao, J., Wu, H., Tseng, T., Liu, C., Yang, H., Su, T., Chen, D., Chen, D.-S., & Liu, C. (2014) · Hepatology International · doi:10.1007/s12072-014-9591-z · Cited by 14
Cited by
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Self-citationChronic Hepatitis B Infection: A Review
Tang, L. S. Y., Covert, E., Wilson, E., & Kottilil, S. (2018) · JAMA · doi:10.1001/jama.2018.3795 · Cited by 657
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572
Self-citationA global scientific strategy to cure hepatitis B
Revill, P. A., Chisari, F. V., Block, J. M., Dandri, M., Gehring, A. J., Guo, H., Hu, J., Kramvis, A., Lampertico, P., Janssen, H. L. A., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30119-0 · Cited by 508
Self-citationCornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Self-citation
Metadata
- Authors
- Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G.
- Venue
- Hepatology
- Published
- 2017-08-01
- Volume
- 66
- Issue
- 4
- Pages
- 1296-1313
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2739683242
- Cited by
- 303
- References
- 69
- FWCI
- 22.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.